California rocket fuel: And what about being a first line treatment? - 13/04/16
Résumé |
Introduction |
The association venlafaxine-mirtazapine is currently known as California Rocket Fuel (CRF). Studies show advantage in terms of efficacy and rapid control of depressive symptoms compared to other associations. Venlafaxine is a selective serotonin-noradrenalin reuptake inhibitor and mirtazapine is a noradrenergic-specific serotonergic antidepressant: the result is a potent noradrenergic and serotonergic effect. Studies say that CRF should be performed only for drug-resistant depression; however, there are case reports of its use as a first line treatment, in selected patients.
Objectives |
To summarize the latest literature about this field and to present a case report.
Aim |
To explore and critically review the controversies of venlafaxine-mirtazapine association as a first line antidepressants strategy.
Methods |
A brief review of the latest literature was performed, using PubMed and the keywords “venlafaxine-mirtazapine association”. A case report about a depressed woman is presented.
Results |
Despite most studies are referent to its utility in drug-resistant depression, there are recent pilot studies that recommend CRF as a first line option.
M., a 64-year-old woman, had her first psychiatric consultation. She had been depressed for 2 years, she lost 10kg, had total insomnia and suicidal thoughts. CRF was started up to 150/15mg, daily. An improvement was noticed after two weeks of treatment and the stabilization of depressive symptoms were achieved by the fourth month.
Conclusions |
CRF seems to be effective and useful. Patients with insomnia and weight loss may benefit from CRF as a first line option. However, more studies are needed.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° S
P. S551 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?